Caffeine Consumption in Glaucoma Patients and Healthy Subjects
ConditionGlaucoma, Primary Open Angle
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-90
SponsorWills Eye
About this trial
Caffeine is the most widely consumed drinking nutrient in the world. Caffeine effects various organs and the vascular system. It decreases ocular blood flow due to vasoconstriction.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
age 18 to 90 years
diagnosis of primary open angle glaucoma (Mild, Moderate and Advanced)
healthy subjects with no eye disease
Disqualifiers
Diseases, ophthalmic or systemic, that are likely to affect OCTA results
greater than moderate cataract
nystagmus
inability to look at target
Trial design
Design model
Parallel
Treatments tested in this trial
Caffeine tablet
Dietary supplementEach eligible participant will receive one 200 mg caffeine tablet to ingest after completing all baseline study tasks.
Treatment groups
80 Participants
are divided into 2 treatment groupsGroup A: Glaucoma PatientsActive comparator 1 intervention
Group B: Healthy controlsActive comparator 1 intervention
Trial outcomes
Primary outcomes
1
Blood flow change in back of eye before and after caffeine
Optical Coherence Tomography Angiography (OCTA) will be obtained using the Avanti AngioVue High Definition (HD) OCTA by Optovue. Images will include standard 4.5mm HD disc scan, 6mm HD retina scan, regular optic nerve head (ONH) structural scan, 3D-disc baseline scan and a regular ganglion cell complex analysis (GCCA) structural scan. This will measure blood flow changes in the back of the eye by imaging vessel density in percentage before then 1 and 2 hours after caffeine.
Time frame
Baseline, Hour 1, Hour 2 Source ClinicalTrials.gov